Suppr超能文献

复发性头颈部腺样囊性癌患者的根治性高剂量再照射:治疗结果及失败模式分析

Curative high-dose reirradiation for patients with recurrent head and neck adenoid cystic carcinomas: outcomes and analysis of patterns of failure.

作者信息

Mahé Mathilde, Beddok Arnaud, Goudjil Farid, Ala Eddine Catherine, Bolle Stéphanie, Champion Laurence, Feuvret Loïc, Herman Philippe, Zefkili Sofia, Choussy Olivier, Le Tourneau Christophe, Dendale Remi, Buvat Irene, Sauvaget Elisabeth, Créhange Gilles, Calugaru Valentin

机构信息

Radiation Oncology Department. Paris/Saint-Cloud/Orsay, Institut Curie. PSL Research University, Paris, France.

Institut Curie. PSL Research University. University Paris Saclay. Inserm LITO U1288 Orsay, Paris, France.

出版信息

Int J Radiat Biol. 2024;100(1):79-86. doi: 10.1080/09553002.2023.2242934. Epub 2023 Aug 21.

Abstract

BACKGROUND

To investigate the outcomes of patients who underwent curative reirradiation (reRT), with intensity-modulated radiation therapy (IMRT) or proton therapy (PT) for unresectable recurrent or second primary head and neck adenoid cystic carcinoma (HNACC).

METHODS

Ten patients, mostly KPS 90%, were reirradiated (3/10 with IMRT and 7/10 with PT) at a median maximum dose to the CTV of 64.2 Gy from July 2011 to November 2021. Locations at the time of reRT were mainly the sinus (4/10) and the salivary glands (including the parotid and submandibular gland, 3/10). CTCAEv5 was used to assess acute and late toxicities. Follow-up was the time between the end of reRT and the date of last news.

RESULTS

The median time between the two irradiations was 53.5 months (IQR: 18-84). After a median follow-up of 26 months (range, 12.5-51.8 months), six patients had developed a locoregional recurrence (LR), of which four occurred within the previously irradiated volume. Two and three-year locoregional failure-free survival (LFFS) and overall survival (OS) were 55.6% [95%CI: 31-99.7%], and 41% [18.5-94%] and 66.7% [42-100%] and 44.4% [21.4-92.3%], respectively. LFFS and OS were significantly better in the subgroup of sinus tumors () and the subgroup of patients re-irradiated more than two years after the first course of irradiation (). Seven patients had impairments before the start of reRT, including hearing impairment (3/10) and facial nerve impairment (3/10). The most severe late toxicities were brain necrosis (2/10), osteoradionecrosis (1/10) and vision decreased (1/10).

CONCLUSION

Curative reRT for HNACC is possible for selected cases, but the LR rate in the irradiated field and the risk of severe toxicity remain high. Improved selection criteria and more carefully defined target volumes may improve outcome in these patients. A further study including larger cohort of patients would be useful to confirm these results.

摘要

背景

研究接受根治性再程放疗(reRT)的患者的治疗结果,这些患者采用调强放射治疗(IMRT)或质子治疗(PT)治疗不可切除的复发性或第二原发性头颈部腺样囊性癌(HNACC)。

方法

2011年7月至2021年11月,对10例患者进行了再程放疗(10例中有3例采用IMRT,7例采用PT),CTV的中位最大剂量为64.2 Gy。再程放疗时的部位主要是鼻窦(10例中有4例)和唾液腺(包括腮腺和颌下腺,10例中有3例)。采用CTCAEv5评估急性和晚期毒性。随访时间为再程放疗结束至最后一次消息日期之间的时间。

结果

两次放疗之间的中位时间为53.5个月(IQR:18 - 84)。中位随访26个月(范围12.5 - 51.8个月)后,6例患者出现局部区域复发(LR),其中4例发生在先前放疗区域内。两年和三年的局部区域无失败生存率(LFFS)和总生存率(OS)分别为55.6%[95%CI:31 - 99.7%]和41%[18.5 - 94%],以及66.7%[42 - 100%]和44.4%[21.4 - 92.3%]。鼻窦肿瘤亚组和首次放疗后两年以上接受再程放疗的患者亚组的LFFS和OS明显更好。7例患者在再程放疗开始前存在功能障碍,包括听力障碍(10例中有3例)和面神经功能障碍(10例中有3例)。最严重的晚期毒性反应为脑坏死(10例中有2例)、骨放射性坏死(10例中有1例)和视力下降(10例中有1例)。

结论

对于部分病例,HNACC的根治性再程放疗是可行的,但放疗区域内的LR率和严重毒性风险仍然很高。改进选择标准和更精确地定义靶区体积可能会改善这些患者的治疗结果。纳入更大患者队列的进一步研究将有助于证实这些结果。

相似文献

4
Reirradiation of Recurrent and Second Primary Head and Neck Cancer With Proton Therapy.质子治疗复发性和第二原发性头颈癌的再照射
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):808-819. doi: 10.1016/j.ijrobp.2016.07.037. Epub 2016 Aug 3.
9
Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience.碳离子再放疗治疗复发性头颈部肿瘤:单机构经验。
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):803-811. doi: 10.1016/j.ijrobp.2019.07.021. Epub 2019 Jul 23.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验